GENE ONLINE|News &
Opinion
Blog

Partnerships
Gilead Sciences Promises $5 million to Combat Monkeypox Public Health Emergency
2022-08-09
Amgen Lays Down $3.7 Billion For ChemoCentryx and its Autoimmune Portfolio
2022-08-04
Roche Dives Deeper into Off-The-Shelf Cell Therapies in Poseida Partnership
2022-08-04
Moderna to Supply 66 Million COVID-19 Boosters to US
2022-07-29
Verve and Vertex Agree to Co-Develop In Vivo Gene Editing Program for Liver Disease
2022-07-21
Roche Offers Up to $1 Billion for Avista to Develop Eye Disease Vectors
2022-07-20
Nestlé Lays Down €40 Million on Enterome’s Food Allergy and IBD Candidate
2022-07-19
Orion Collects $290 Million From Merck in Prostate Cancer Development Collaboration
2022-07-14
NIH Launches mRNA Nipah Virus Vaccine Trial With Moderna
2022-07-12
Astellas and Sutro Team Up for Immunostimulatory Antibody-Drug Conjugates (iADCs)
2022-06-28
Valneva Receives Funding From Pfizer to Develop World’s Only Lyme Disease Vaccine
2022-06-21
Gilead Sciences Works Alongside Westminster Drug Project To Eliminate Hepatitis C
2022-06-09
NVIDIA & Singular Genomics Team Up to Boost Next-Gen Sequencing Capabilities
2022-05-11
LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!